Redeye maintains its positive view of Transtema following a Q4 showing a better q/q margin improvement than expected. Although Q1 2024 likely will be soft due to adverse weather, reduced costs, new deals, and a somewhat improving market, set Transtema for gradual improvements of margins and organic growth rates in 2024.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema - Rebound in Margins

© Modular Finance, source Nordic Press Releases